New Product Newswire

A new option for adults who have experienced stroke will now be available to further reduce future risk.

Findings from a meta-analysis of over 125 clinical trials led the agency to require a class-wide label change.

Gilead’s current lenacapavir patent is what makes Dr Reddy’s Laboratories’ formulation tentative.